EA202091293A1 - Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 - Google Patents

Производные пиридинона и их применение в качестве селективных ингибиторов alk-2

Info

Publication number
EA202091293A1
EA202091293A1 EA202091293A EA202091293A EA202091293A1 EA 202091293 A1 EA202091293 A1 EA 202091293A1 EA 202091293 A EA202091293 A EA 202091293A EA 202091293 A EA202091293 A EA 202091293A EA 202091293 A1 EA202091293 A1 EA 202091293A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
present
pyridinone derivatives
selective alk
alk
Prior art date
Application number
EA202091293A
Other languages
English (en)
Inventor
Лука Ариста
Сильви Шамуан
Пьер Лука Д'Алессандро
Мика Линдвалль
Димитриос Лизос
Николаус Йоханнес Штифль
Сильви Тейшейра-Фушар
Томас Улльрих
Свен Вайлер
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA202091293A1 publication Critical patent/EA202091293A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Настоящее изобретение относится к соединению формулы (I) или его фармацевтически приемлемой солиспособу получения соединений по настоящему изобретению и вариантам их терапевтического применения. В настоящем изобретении дополнительно представлена комбинация фармакологически активных средств и фармацевтическая композиция.
EA202091293A 2017-11-24 2017-11-24 Производные пиридинона и их применение в качестве селективных ингибиторов alk-2 EA202091293A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
EA202091293A1 true EA202091293A1 (ru) 2020-11-23

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091293A EA202091293A1 (ru) 2017-11-24 2017-11-24 Производные пиридинона и их применение в качестве селективных ингибиторов alk-2

Country Status (24)

Country Link
US (1) US11160797B2 (ru)
EP (1) EP3713927B1 (ru)
JP (1) JP7091455B2 (ru)
KR (1) KR20200091422A (ru)
CN (1) CN111433195B (ru)
AU (1) AU2017440306B2 (ru)
BR (1) BR112020010171A2 (ru)
CA (1) CA3081651A1 (ru)
CL (1) CL2020001277A1 (ru)
CO (1) CO2020005885A2 (ru)
CR (1) CR20200211A (ru)
CU (1) CU20200035A7 (ru)
DO (1) DOP2020000088A (ru)
EA (1) EA202091293A1 (ru)
EC (1) ECSP20026023A (ru)
ES (1) ES2908252T3 (ru)
IL (1) IL274722A (ru)
JO (1) JOP20200127A1 (ru)
MX (1) MX2020005405A (ru)
PE (1) PE20201282A1 (ru)
PH (1) PH12020550763A1 (ru)
RU (1) RU2020120538A (ru)
SG (1) SG11202003920QA (ru)
WO (1) WO2019102256A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220401445A1 (en) * 2020-04-30 2022-12-22 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332779T2 (de) 1992-11-17 2003-10-23 Ludwig Inst For Cancer Res Pad Aktivin-rezeptor-ähnliche kinasen, proteine mit serin/threonin kinase domänen und deren anwendungen
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
KR20090088852A (ko) 2006-09-05 2009-08-20 메다렉스, 인코포레이티드 골형성 단백질의 항체와 이의 수용체 및 이의 사용방법
US20100093760A1 (en) 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
CA3034600C (en) * 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
SG187589A1 (en) 2010-08-20 2013-03-28 Wyeth Llc Designer osteogenic proteins
CN103402520A (zh) 2010-12-06 2013-11-20 皮拉马尔企业有限公司 具有取代基的咪唑并喹啉衍生物
SI2820009T1 (en) 2012-03-01 2018-05-31 Array Biopharma, Inc. Serine / Threonine kinase inhibitors
JP2017514793A (ja) * 2014-03-26 2017-06-08 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
US20170305883A1 (en) * 2014-10-01 2017-10-26 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting BMP
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives

Also Published As

Publication number Publication date
US11160797B2 (en) 2021-11-02
CL2020001277A1 (es) 2020-11-13
EP3713927B1 (en) 2021-12-15
PH12020550763A1 (en) 2021-04-26
CU20200035A7 (es) 2021-03-11
CO2020005885A2 (es) 2020-07-31
ECSP20026023A (es) 2020-07-31
WO2019102256A1 (en) 2019-05-31
CN111433195B (zh) 2023-04-25
SG11202003920QA (en) 2020-06-29
JP7091455B2 (ja) 2022-06-27
ES2908252T3 (es) 2022-04-28
JOP20200127A1 (ar) 2020-05-21
CA3081651A1 (en) 2019-05-31
RU2020120538A3 (ru) 2021-12-24
EP3713927A1 (en) 2020-09-30
IL274722A (en) 2020-07-30
AU2017440306A1 (en) 2020-05-21
PE20201282A1 (es) 2020-11-24
AU2017440306B2 (en) 2021-01-28
CN111433195A (zh) 2020-07-17
RU2020120538A (ru) 2021-12-24
KR20200091422A (ko) 2020-07-30
DOP2020000088A (es) 2020-08-31
CR20200211A (es) 2020-06-19
JP2021512850A (ja) 2021-05-20
BR112020010171A2 (pt) 2020-11-03
US20200360357A1 (en) 2020-11-19
MX2020005405A (es) 2020-08-13

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
EA201591499A1 (ru) Замещенные бисфенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии
PH12016502247A1 (en) Carboxamide derivatives
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний